Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 12/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 5/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280570 | 1.00 | VDR (0.47) | VDRMAOBNR4A2MAOANR4A1 | |
| SCHEMBL3280573 | 1.00 | VDR (0.47) | VDRMAOBNR4A2MAOANR4A1 | |
| SCHEMBL4551473 | 0.92 | VDR (0.43) | VDRMAOBNR4A2MAOANR4A1 | |
| SCHEMBL4551470 | 0.92 | VDR (0.43) | VDRMAOBNR4A2MAOANR4A1 | |
| SCHEMBL3280271 | 0.81 | VDR (0.48) | VDRMAOBNR4A2MAOANR4A1 | |
| SCHEMBL6887724 | 0.78 | MRGPRX4 (0.53) | MAOBNR4A2SMPD1 | |
| SCHEMBL6883961 | 0.77 | MRGPRX4 (0.55) | MAOBNR4A2SMPD1 | |
| SCHEMBL6566359 | 0.76 | MRGPRX4 (0.66) | MAOBNR4A2NR4A1NR4A3SMPD1 | |
| SCHEMBL6882555 | 0.75 | MRGPRX4 (0.55) | MAOBNR4A2SMPD1 | |
| SCHEMBL6566172 | 0.74 | MRGPRX4 (0.63) | NR4A2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700657-B2 | Vitamin D analogs | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-20 | — | — | US | disclosed |
| US-20040224929-A1 | Novel vitamin D analogs | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-11-11 | — | — | US | disclosed |